Dynavax Technologies Corporation provided a regulatory update for the Company’s supplemental Biologics License Application (sBLA) to include a four-dose Heplisav- B vaccine [Hepatitis B Vaccine (Recombinant),Adjuvanted] regimen for… read more.
At the European Congress on Obesity in Venice, investigators unveiled results from an analysis published in Nature Medicine evaluating Wegovy’s weight loss benefits over four years. With this… read more.
Bristol Myers Squibb announced the Phase III CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell… read more.
Moberg Pharma AB hereby announces that MOB 015 has received national approvals for all countries included in the decentralized procedure. MOB 015 is thus approved for the treatment… read more.
Sobi has announced that the European Commission (EC) has approved an indication extension for Aspaveli (pegcetacoplan) for treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have… read more.
Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced that the FDA has approved… read more.
UCB announced the final three-year open-label extension (OLE) study results of Fintepla (fenfluramine) in Dravet syndrome are being presented at the International Child Neurology Congress (ICNC), May 6-10,… read more.
Medtronic announced it received approval from the National Medical Products Administration (NMPA) in China for its Symplicity Spyral renal denervation (RDN) system, also known as the Symplicity blood… read more.
Edwards Lifesciences announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough RESILIA tissue technology, designed… read more.
Eyenovia announced results from a Phase IV study of Mydcombi designed to characterize the lowest deliverable dose for mydriasis (pupil dilation). Mydcombi is the only FDA-approved fixed dose… read more.
Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with… read more.
FRAIL-AF trial investigators set out to study the question of whether frail, elderly patients with atrial fibrillation who were doing well with vitamin K antagonists (VKA) should be… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
